For the quarter ending 2025-11-30.
| Income Statement | 2025-11-30 | 2025-08-31 | ||
|---|---|---|---|---|
| Revenue | 0 | 176 | ||
| Cost of goods sold | 0 | 1 | ||
| Gross profit | 0 | 176 | ||
| Research and development | 671.34 | 2,060 | ||
| General and administrative | 902.291 | 1,086 | ||
| Total operating expenses | 1,573.631 | 3,146 | ||
| Loss from operations | -1,573.631 | -2,970 | ||
| Interest income | 0.012 | 1 | ||
| Unrealized loss on marketable securities | -22.093 | -8 | ||
| Total other income (loss) | -22.081 | -8 | ||
| Net loss before income taxes | -1,595.712 | - | ||
| Income taxes | 1.791 | - | ||
| Net loss | -1,597.503 | -2,978 | ||
| Less net loss attributable to non-controlling interest | -2.496 | -2 | ||
| Net loss attributable to lexaria shareholders | -1,595.007 | -2,975 | ||
| Foreign currency translation adjustment | -5.744 | -13 | ||
| Total comprehensive loss | -1,600.751 | -2,988 | ||
| - basic and diluted | 21,376,029 | 4,499,678.75 | ||
| Basic and diluted loss per share | -0.07 | -0.165 | ||
Lexaria Bioscience Corp. (LEXXW)
Lexaria Bioscience Corp. (LEXXW)